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Craniofrontonasal syndrome (CFNS) is an X-linked disorder that exhibits a paradoxical sex reversal in phenotypic
severity: females characteristically have frontonasal dysplasia, craniosynostosis, and additional minor malforma-
tions, but males are usually mildly affected with hypertelorism only. Despite this, males appear underrepresented
in CFNS pedigrees, with carrier males encountered infrequently compared with affected females. To investigate
these unusual genetic features of CFNS, we exploited the recent discovery of causative mutations in the EFNB1
gene, which encodes ephrin-B1, to survey the molecular alterations in 59 families (39 newly investigated and 20
published elsewhere). We identiﬁed the ﬁrst complete deletions of EFNB1, catalogued 27 novel intragenicmutations,
and used Pyrosequencing and analysis of nearby polymorphic alleles to quantify mosaic cases and to determine
the parental origin of veriﬁed germline mutations. Somatic mosaicism was demonstrated in 6 of 53 informative
families, and, of 17 germline mutations in individuals for whom the parental origin of mutation could be dem-
onstrated, 15 arose from the father. We conclude that the major factor accounting for the relative scarcity of carrier
males is the bias toward mutations in the paternal germline (which present as affected female offspring) combined
with reduced reproductive ﬁtness in affected females. Postzygotic mutations also contribute to the female prepon-
derance, whereas true nonpenetrance in males who are hemizygous for an EFNB1 mutation appears unusual. These
results highlight the importance of considering possible origins of mutation in the counseling of families with CFNS
and provide a generally applicable approach to the combined analysis of mosaic and germline mutations.
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Craniofrontonasal syndrome (CFNS [MIM 304110]),
ﬁrst clearly delineated in 1979,1,2 is a distinctive disorder
characterized by severe hypertelorism with a grooved
nasal tip, coronal synostosis (unilateral or bilateral), ﬁne
frizzy hair, abnormal modeling of the clavicles, partial
cutaneous syndactyly of the hands and feet, and longi-
tudinal ridging of the nails. Cleft lip and/or palate,
Sprengel shoulder, duplication of the thumbs or halluces,
partial or complete agenesis of the corpus callosum, and
learning difﬁculties occur in a proportion of cases.3 Over
a 10-year period at the Oxford Craniofacial Unit, CFNS
accounted for 6 of 287 prospectively ascertained cases
that required an operation for craniosynostosis, which
indicates a birth prevalence of ∼1 in 120,000 (S.A.W.
and A.O.M.W., unpublished data).
The genetic counseling of families with CFNS has been
problematical because of the unusual inheritance pattern
of CFNS. The great majority of individuals who present
with classic CFNS are females; only a small number of
males with an apparently similar phenotype have been
described.4,5 Usually, this sex bias in manifestation is
caused by the segregation of an X-linked male-lethal mu-
tation; indeed, this mechanism was proposed for CFNS.6
However, this explanation became untenable with the
description of multiple pedigrees in which classically af-
fected females were linked through an intermediatemale
relative.2,7–9 These obligate carrier males were always
more mildly affected than were affected females, with a
nonspeciﬁc phenotype comprising hypertelorism and oc-
casional cleft lip. Nevertheless, the observation that the
daughters of these male carriers invariably had CFNS
supported the segregation of an X-linked mutation that,
paradoxically, seemed to affect heterozygous females
more severely than hemizygous males.8
Table 1
Clinical Features and Molecular Analysis of the Newly Analyzed EFNB1 Mutation
PROBAND (NO. AND
SEX OF MUTATION-
POSITIVE SUBJECTS
ANALYZED)
CLINICAL FEATURESa MUTATIONb
Coronal
Craniosynostosis
Cleft Lip
and/or
Palate
Duplex Thumb
or Hallux
Agenesis of
the Corpus
Callosum Other DNA Exon (Intron) Protein Familial or Sporadic Conﬁrmation Mosaicismc
Parental
Origind
3205 (1 F)     … 4_4del 1  S BslI()  U
3350 (1 F) L  RH  Developmental delay 30CrT 1 K11SfsX2e S ASO  NI
3259 (1 F) R and L    Sprengel deformity 109TrG 1 W37G S BstXI()f  U
3429 (1 F) R and L    Hypertrophic cardiomyopathy 109TrG 1 W37G Fam (2 F) BstXI()f NA U
3605 (1 F and 1 M) R    Duplex kidney, Bartholin cyst 110GrA 1 W37X Fam (1 F and 1 M) BslI()  PZ(M)
3533 (1 F)   LH Partial … 123CrG 1 N41K S SmlI()  Mat
3504 (1 M and 2 F) L    Diaphragmatic hernia in son 151_153delGTG 2 V51del Fam (1 M and 4 F) HphI() NA U
3217 (2 F and 1 M) R    … 161CrT 2 P54L Fam (1 F and 1 M) BslI()  PZ(F)
3556 (1 F)     … 170_171GArTT 2 G57V S BslI()  U
3412 (1 F)    U … 191GrA 2 C64Y Fam (2 F) MwoI()f  PZ(F)
3553 (2 F and 1 M) L   U … 196delC 2 R66EfsX93 Fam (1 F and 1 M) BglI()f  PZ(F)
3204 (1 F) L    Intracranial dermoid and double uterus 196CrT 2 R66X S AvaI()  U
3518 (1 F) R and L CL, P   … 196CrT 2 R66X S AvaI()  Pat
3549 (1 F) L CL, P RH and LH Partial Developmental delay 196CrT 2 R66X S AvaI()  U
3516 (1 F) R and L  RH  … 220GrT 2 E74X S HinfI()f  U
3281 (3 F) R and L    Sprengel deformity 233TrC 2 L78P Fam (3 F) BceAI()  U
3638 (1 F) R   Partial Duplex left kidney 265TrC 2 C89R S SfcI()  NI
3347 (1 F) L    Ulnar clinodactyly, right middle ﬁnger 266GrA 2 C89Y S Hpy8I()f  U
3262 (1 F) R and L    … 339GrC 2 K113N S Hpy8I()f  Pat
3608 (2 F and 1 M) R and L    … 355CrG 2 P119A Fam (3 F and 1 M) HhaI() NA U
3575 (1 F) R and L    Cerebellar dysplasia and vesico-ureteric reﬂux 363CrA 2 Y121X S NlaIII()  Pat
3258 (1 F and 1 M) R and L    … 368GrA 2 G123D Fam (1 F and 1 M) AvaII()  (M) U
3213 (1 F)   LH Partial Developmental delay 398delA 2 Y133SfsX26 S ASO  U
3494 (1 F) R    … 407-1GrA (2) SP S PstI()  PZ(F)
3618 (1 F)  P (uvula) RT  Developmental delay 407CrT 3 S136L S TseI()  Pat
3410 (1 M and 1 F)  CL and P   Diaphragmatic hernia and sacrococcygeal
teratoma in son
432delG 3 L145WfsX14 Fam (1 M and 1 F) BglI()  U
3563 (1 F) R P   … 445GrT 3 E149X S NciI()  U
3615 (2 F and 1 M) U U U U … 451GrA 3 G151S Fam (4 F and 1 M) AciI() NA U
3576 (1 F) U    Developmental delay 452GrA 3 G151D S AciI()  U
3467 (1 F) R    … 458GrC 3 C153S S MwoI()  Pat
3265 (2 F and 1 M) R and L    Developmental delay 496CrT 3 Q166X Fam (2 F and 1 M) BglI()f  (M) U
3414 (2 F) L   U Developmental delay 500-2ArG (3) SP Fam (4 F) BamHI()  U
3269 (1 F)    U … 564_565insT 4 V189CfsX10 S DrdI()  Pat
3221 (1 F)     … 587delC 4 P196LfsX17 S XcmI()  U
3473 (2 F) L    Right diaphragmatic hernia 635_636delTG 5 V212EfsX19 Fam (2 F) Hpy8I()  U
3319 (1 F) R    Bilateral dysplastic hips 993_994insCT 5 Q332LfsX61 S Hpy188III()  NI
3214 (1 F) R and L    … Deletion 1–5 … S Southern MLPA  Mat
3487 (2 F) L   Partial Mother has bicornuate uterus Deletion 1–3 … Fam (2 F) Southern MLPA  Mat
3558 (1 F) R    Sensorineural hearing loss Deletion 1–5 … S MLPA  Pat
NOTE.—Totals include mosaic cases. The 27 newly described intragenic mutations are shown in bold italics. U p unknown.
a A plus sign () p present; a minus sign () p absent; R p right side affected; L p left side affected; CL p cleft lip; P p cleft palate; T p duplex thumb; H p duplex hallux.
b SP p splice-site mutation; S p sporadic case; Fam p familial mutation; ASO p allele-speciﬁc oligonucleotide hybridization.
c A plus sign () p proven mosaicism; a minus sign () p no mosaicism found; NA p not applicable. One somatic mosaic was identiﬁed in a family published elsewhere.10
d Pat p paternal origin; Mat p maternal origin; PZ p postzygotic origin (in F or M fetus); NI p not informative. Seven paternally originating germline mutations (344, 347, 372, 656, 723, 1219, and 2613) were identiﬁed in cases published
elsewhere.10
e RNA analysis shows that this apparently synonymous substitution creates a cryptic donor splice site.
f Mutant oligonucleotide/digest.
www.ajhg.org The American Journal of Human Genetics Volume 78 June 2006 1001
Table 2
Primers Used for the Ampliﬁcation of SNPs and CA
Microsatellites
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 3
Primers Used for Parental-Origin Analysis by Allele-
Speciﬁc PCR
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Although generally accepted, this proposed inheritance
pattern raised two major difﬁculties. The ﬁrst was to
explain how an X-linked mutation could result in amore
severe phenotype in a heterozygous female than in a
hemizygous male. Substantial insight into this issue was
recently achieved with the identiﬁcation ofEFNB1 (Gen-
Bank accession numbers AL136092 and NM_004429),
which encodes the cell-surface signaling molecule ephrin-
B1, as the major gene mutated in CFNS.10,11 This discov-
ery conﬁrmed that CFNS is X linked, because EFNB1 is
located at Xq13.1. Moreover, targeted inactivation of the
mouse ortholog Efnb1 results in a similar paradoxical
pattern of phenotypic severity, with heterozygous females
consistently more severely affected than hemizygous
males.12,13 In the heterozygous female mice, abnormal
sorting of cells into ephrin-B1–expressing and –nonex-
pressing patches was shown to correlate with the X-in-
activation status of Efnb1.12 As a result, ectopic tissue
boundaries between these patches are generated, which
lead to morphological abnormalities speciﬁcally in het-
erozygous females; these females are functional mosaics
because of X inactivation. The term “cellular interfer-
ence” has been proposed for this phenomenon (reviewed
by Wieacker and Wieland14). In hemizygous males, by
contrast, this process cannot occur. Since the diverse na-
ture of EFNB1mutations—including missense, nonsense,
frameshift, and partial gene deletions—implies loss of
function in the protein, the generally mildmale phenotype
suggests that ephrin-B1 is redundant in most tissues in
which it is expressed.
The conﬁrmation that CFNS exhibits a paradoxical
pattern of X-linked inheritance, as well as insight into
its potential mechanism, highlights a second difﬁculty in
explaining the genetics of this disorder. If the male phe-
notype is minor, why are there so few males in CFNS
pedigrees? For example, the comprehensive review by
Grutzner and Gorlin identiﬁed 58 affected females but
only 8 affected/carrier males8; similarly, the nonoverlap-
ping set of pedigrees analyzed in the present study in-
cludes 86 affected females but only 9 carrier males. The
aggregate ﬁgures indicate a signiﬁcant underrepresen-
tation of males compared with the expected 2:1 female:
male ratio for an X-linked mutation at equilibrium. One
possible explanation is that many males with EFNB1
mutations do notmanifest any clinical abnormality.How-
ever, in our initial mutation analysis of 20 unrelated fe-
males with CFNS, we did not ﬁnd a single instance in
which the clinically unaffected father turned out to be a
carrier: either the mutation had arisen de novo or the
clinically affected mother had transmitted the mutation.10
In an attempt to resolve this paradox, we set out to
analyze the molecular origins of EFNB1 mutations in a
large patient cohort. One goal of this work was to de-
termine the parental origin of new germline mutations,
because paternally originating mutations can give rise
only to affected females in the ﬁrst generation.15 Given
the importance of functional mosaicism (through X in-
activation) in the CFNS phenotype, we also wanted to
examine the possibility that somatic mosaicism ofEFNB1
leads to CFNS in either males or females. Collectively,
our work identiﬁes several factors that lead to the under-
representation of males in CFNS pedigrees, the most im-
portant of which is a bias toward new mutations arising
in the paternal germline. Our analysis also reveals a di-
versity of presentations of postzygotic EFNB1 mutations
that require careful consideration for genetic counseling.
Subjects and Methods
Clinical Ascertainment
The study was approved by the Oxfordshire Research Ethics
Committee, and informed consent was obtained from all par-
ticipants by the referring clinicians, in accordance with lo-
cal guidelines. All families were ascertained through a clinic-
ally affected proband exhibiting the characteristic features of
CFNS.3 This work analyzes 59 unrelated families in which a
pathogenic mutation of EFNB1 was identiﬁed. Of these fam-
ilies, 20 were reported elsewhere10 and 39 were recruited for
this study; the latter are unpublished elsewhere except for sub-
jects 3259, 3262, 3258, and 3265, who correspond to subjects
1, 2, 4/8, and 5/6/9, respectively, in the work of Kapusta et
al.4 The clinical features and results of mutation analysis in
these new families are summarized in table 1. We analyzed
peripheral blood samples from all affected individuals and ob-
tained additional buccal brushings and/or hair roots from three
individuals with suspected cases of mosaicism. EFNB1 muta-
tions were not identiﬁed in a further 10 females with suspected
CFNS referred by clinical geneticists, nor in 2 sporadic males
with a CFNS-like phenotype.
Informativity for Analysis of Mutational Origin
Of the 59 families studied, 20 families had two or more
affected individuals (samples were available from 42 individ-
uals: 33 females and 9 males); the remaining 39 families had
sporadically affected females. We distinguished among three
categories of family sampling. In category 1 ( ), no samplenp 6
was available from the ﬁrst affected individual in the family,
so that attempts to determine mutational origin were not ap-
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Table 4
Miscellaneous Primers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 5
Primers Used for Genotyping of Mutations and SNPs
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
plicable. In category 2 ( ), a sample was available fromnp 27
the ﬁrst affected individual in the family but not from both
clinically unaffected parents (only the maternal sample was
required in the case of a ﬁrst affected male). These samples
were informative for mosaicism only. In category 3 ( ),np 26
availability of samples from both parents of a ﬁrst affected
child rendered the family potentially fully informative for both
mosaicism and parental origin. This third category includes an
additional subject (individual 373), for whom parental samples
were obtained subsequent to the original publication.10
Detection of EFNB1 Mutations
Intragenic mutations of EFNB1 were detected by a com-
bination of PCR, Wave denaturing high-performance liquid
chromatography (DHPLC), and DNA sequencing, as described
elsewhere.10 Additional PCR ampliﬁcations, performed with
the primer pairs and conditions shown in tables 2–6 (online
only), used the same reagents,10 except that the Pwo poly-
merase was omitted for non–Wave DHPLC applications. All
mutations were conﬁrmed independently, mostly by restriction
enzyme digest; in cases where the mutation did not alter a
restriction site, a primer containing a mismatch was designed
to amplify the mutation, to introduce a suitable restriction site
(preferably for the wild-type allele) (table 5). In two samples,
allele-speciﬁc oligonucleotide hybridization was used for con-
ﬁrmation (table 6). To assess the likely effects of amino acid
substitutions in ephrin-B1, residue contacts in the ephrin-B2/
EphB2 structure17 were obtained with CSU software (see the
LPC CSU Server).18
In samples that had normal results in the mutation screen
described above, the possibility of a deletion in EFNB1 was
sought. Six polymorphic (CA)n microsatellites (table 2 [online
only]) surrounding EFNB1 were ampliﬁed, and the products
were separated by electrophoresis and were analyzed by blot
hybridization with a 32P-dCTP–labeled (CA)10 probe. Apparent
noninheritance of alleles at more than one locus indicated the
existence of a deletion and demonstrated its parental origin.
Deletions were conﬁrmed using the multiplex ligation-depen-
dent probe ampliﬁcation (MLPA) P080 Craniofacial kit (MRC
Holland). In patient 3214, after approximate localization of
the breakpoints with Southern blot hybridization, a diagnostic
breakpoint fragment was PCR ampliﬁed (table 4 [online only])
and sequenced.
Quantiﬁcation of Mosaicism by Pyrosequencing
Single-stranded PCR products were obtained using a bio-
tinylated primer (table 7) and immobilization to streptavidin
beads, denatured with NaOH and annealed to the sequencing
primer by heating to 80C for 2 min. Pyrosequencing19 was
performed on three independent PCRs from control and pa-
tient samples, with use of primers and dispensation orders
designed to quantify each mutant (M) and corresponding nor-
mal control (NC) allele (table 7 and ﬁg. 1), on a PSQ-HS96A
system (Biotage). Peak heights were obtained using the Pyro-
sequencing software and were exported to an Excel spread-
sheet. We extracted the heights of all independent pairs of
dispensation peaks for the same nucleotide and speciﬁc to ei-
ther the NC or the M alleles; where possible, these pairs rep-
resented the same nucleotide position extended at different
dispensations (ﬁg. 1). In two cases, it was necessary to compare
a double peak for one allele with a single peak for the other
allele; in those cases, we halved the height of the double peak
before comparing the two measurements. We rejected dispen-
sations when the average value of exceeded 0.07M/(MNC)
in the normal control sample. We used the same calculation
(corrected for background, estimated from a blank dispensa-
tion included in each assay) to estimate the proportion of mu-
tant allele in the patient samples. One to four independent
estimates of this proportion were obtained for each PCR (ﬁg.
1); these estimates were averaged and then were compared
among the three separate reactions.
Parental Origin of EFNB1 Mutations
We used approaches described elsewhere16,20 to determine
from which parent the mutation had arisen. Probands from
fully informative families were assessed for heterozygosity at
microsatellite polymorphisms or at SNPs located within 1.8
kb of the particular mutation. Informative polymorphisms
were a (CA)n microsatellite within intron 1 (CA c.129–485)
(families 344, 372, 656, 2613, 3262, 3269, 3467, 3518, 3575,
and 3618) and four SNPs, two newly identiﬁed in the present
study, employed in the single families 3533 (dbSNP rs421069),
1219 (dbSNP ss49854052), 723 (dbSNP rs626840), and 347
(dbSNP ss49854051) (ﬁg. 2). The methods used to deduce the
phase of the mutation with respect to the polymorphism are
detailed in tables 3 and 4 (online only). Correct relationships
of DNA in sample trios were conﬁrmed using a minimum of
eight microsatellites, with a minimum heterozygosity of 67%
(GDB Human Genome Database) and located on different
chromosomes.
Results
In 49 consecutively referred, unrelated female patients
with suspected CFNS, we identiﬁed 39 EFNB1 muta-
tions (table 1), of which 36 were intragenic and 3 were
partial ( ) or complete ( ) gene deletions. Thenp 1 np 2
36 intragenic mutations comprised 20 single-nucleotide
and 1 double-nucleotide substitutions encodingmissense
( ) or nonsense ( ) codons, frameshifting de-np 15 np 6
letions ( ) or insertions ( ) of 1–2 nt, splicingnp 5 np 2
mutations ( ), and initiation codon and in-framenp 3
deletion mutations (one each). Two mutations, W37G
and R66X, were found recurrently. Of the intragenic mu-
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Figure 1 Quantiﬁcation of EFNB1 mutations by Pyrosequenc-
ing. The legend is available in its entirety in the online edition of The
American Journal of Human Genetics.
Table 6
Oligonucleotides Used for Conﬁrmation of Mutations
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 2 Scale map of the EFNB1 gene showing key polymorphic sites and primers used in the analysis. Positions of (CA)n repeats and
SNPs are shown beneath the EFNB1 exons, which are boxed and numbered 1–5. Above, Numbered dotted lines connecting pairs of arrows
correspond to PCR products and primer pairs featured in tables 2–4 (online only). Allele-speciﬁc primers are indicated in gray.
tations, 27 are newly described (indicated in bold italics
in table 1); the majority predict gross disruption of the
protein. Of the 12 novel missense mutations, 5 locate
at residues (W37, C89, P119, and G151) at which mul-
tiple independent substitutions have occurred in CFNS;
5 (N41K, C64Y, C89R, K113N, and S136L) were shown
to have arisen de novo (see below). Of the substitutions
not fulﬁlling either of these criteria (G57V, L78P, and
G123D), two are familial and segregated with the phe-
notype (a total of ﬁve affected individuals); all are non-
conservative and locate at residues highly conserved in
vertebrate B-type ephrins.10 It is therefore likely that all
the missense mutations that we identiﬁed are pathogenic.
We characterized the three submicroscopic gene de-
letions, using a combination of microsatellite analysis,
MLPA, and Southern blotting (ﬁg. 3). One complete de-
letion (in subject 3214, a de novo case of maternal or-
igin) extended only for a short distance beyond the 5′
end of the gene, excising 14,610 bp (ﬁg. 3). Using prim-
ers ﬂanking the deletion (table 4 and ﬁg. 2), we ampliﬁed
a diagnostic junction fragment in the proband but found
no evidence of its presence in DNA extracted from the
blood of the unaffected mother (not shown). The two
other deletions of EFNB1 (one complete and one partial)
were partially characterized by microsatellite analysis
and were shown to be of paternal origin. The complete
deletion included at least part of the neighboring gene,
STARD8 (GenBank accession numbers AL732324.6 and
AL360076.9), which encodes a RhoGAP protein (ﬁg. 3).
A major goal of our work was to establish the parental
origin of intragenic germline EFNB1 mutations. To en-
sure correct interpretation of these data, it was essential
to avoid contamination with cases of postzygotic origin,
which might show no preference for arising on the pa-
ternal or maternal allele. We hypothesized that even low
levels of somatic mosaicism might manifest in CFNS (in
either females or males), since this could potentially lead
to cellular interference by amechanism analogous to that
resulting from X inactivation. Therefore, our initial ef-
forts were directed at identiﬁcation of somaticmosaicism
in the 53 cases that were potentially informative.
The six instances in which such mosaicism was es-
tablished are shown in ﬁgure 4A. These presented in
three distinct ways, but only one case had been suspected
clinically. This was in family 3217 (ﬁg. 4B, left), in which
the female proband had classic CFNS and her brother
had hypertelorism and a nasal pit, but their mother did
not have any CFNS features apart from slight nasal
asymmetry and longitudinal grooves in her nails. The
EFNB1 mutation 161CrT (P54L), described twice else-
where,11,21 was present in DNA from blood of those three
individuals but not in blood of the father or of the
mother’s parents. Quantiﬁcation of this mutation, by
Pyrosequencing of the mother’s blood, showed a level
indistinguishable from 50%; however, because we sus-
pected that she was a mosaic, we analyzed hair roots
and buccal brushings. On the diagnostic BslI restriction
digests, it was apparent that the mutant allele was un-
derrepresented in these tissues (ﬁg. 4B, right); this was
quantiﬁed for the hair roots by Pyrosequencing (ﬁg. 5).
In three other families (1818, 3412, and 3494), by
contrast, mosaicism was established because the EFNB1
mutation was underrepresented in the blood of a clas-
sically affected female. In one of these (patient 3494),
the EFNB1 mutation 407-1GrA (described by Twigg et
al.10) was not identiﬁable on sequencing of DNA from
blood, but the mutation was revealed because our mu-
tation screening included Wave-DHPLC, which is more
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Table 7
PCR and Pyrosequencing Oligonucleotides
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 3 Complete and partial deletions of EFNB1. A, Scale
diagram showing position of EFNB1 relative to its ﬂanking genes
STARD8 and PJA1 (GenBank accession number AL157699.13). The
(CA)n primer pairs (1, 5, and 7–10) used to detect hemizygosity or
heterozygosity at different positions correspond to numbered PCR
primer pairs featured in table 2 (online only). The extent of conﬁrmed
deletions in three cases is indicated by blackened horizontal bars, with
unblackened boxes that delineate the range of possible deletion break-
points. The centromeric (Cen) extent of deletion in 3558 has not been
determined (dashed lines). Telp telomeric. B, MLPA analysis of sub-
ject 3214 (below) compared with a normal female control (above).
The estimated dose of EFNB1 exons 1–5 in 3214 is approximately
half in comparison with 31 different autosomal amplicons. C, DNA
sequence across EFNB1 deletion in case 3214, compared with the
normal sequences at the centromeric and telomeric ends of the break-
point. There is homology of only 2 nt (TG) at the site where the deleted
sequences are joined.
sensitive than DNA sequencing for detection of trace
amounts of mutation (ﬁg. 4C, left). After cloning the
PCR product that exhibited the abnormal waveform, the
GrA mutation was revealed in 1 of 16 clones sequenced
(ﬁg. 4C, middle). The diagnostic PstI restriction digest
conﬁrmed that the mutant allele was underrepresented
(ﬁg. 4C, right), and this was quantiﬁed as 13% by Py-
rosequencing (ﬁg. 5). In contrast, the other two cases
had higher levels of the mosaic mutation in blood, but
these levels were quantiﬁably !50%. We initially sus-
pected these cases either because the mutant allele ap-
peared underrepresented on the DNA sequencing chro-
matogram (ﬁg. 4D, left) or by comparison of the inten-
sities of the normal control and the mutant alleles in the
conﬁrmatory restriction digests (see the “Discussion”
section; for examples, see ﬁg. 4B and 4C). We conﬁrmed
the mosaicism by quantiﬁcation of the allelic propor-
tions, using Pyrosequencing (ﬁg. 4D, right, and ﬁg. 5).
In the third group (families 3553 and 3605), the
asymptomatic parent of a sporadic affected individual
was found to be a mosaic (ﬁg. 4A). Only 24 families
(those in category 3, except for subjects 3487 and 3558
with the larger de novo deletions) could be tested for
this type of mosaicism. In family 3553, the only clinical
manifestation in the mosaic grandmother was marked
longitudinal nail ridges (noted retrospectively). The other
case, the father in family 3605, is the ﬁrst male mosaic
to be identiﬁed with an EFNB1 mutation. His facial
features appeared mildly dysmorphic with nasal asym-
metry, but he did not have signiﬁcant telecanthus (inner
canthal distance 35 mm; 1.6 SD). In both of these
cases, the level of mosaicism was quantiﬁed at 13%
(ﬁgs. 4A and 5), but the mutation was detected on di-
agnostic restriction digests of multiple tissues.
No other cases of mosaicism were found, either by
examination of the relative heights of normal control
and mutant peaks on DNA sequence chromatograms or
of relative fragment intensity on restriction digests (data
not shown). However, since we recognized that both
these methods are subjective, we quantiﬁed the relative
amounts of normal and mutant alleles by Pyrosequenc-
ing (ﬁg. 1). We selected four classes for analysis: (1)
suspected cases of mosaicism (described above), (2) fa-
milial mutations in which a ﬁrst-generation affected in-
dividual (potential mosaic) could be compared with a
second-generation offspring (germline mutation), (3) mu-
tations in which multiple independent cases were avail-
able for comparison, and (4) all cases in which we deter-
mined the parental origin of mutation (see below). The
results are illustrated in ﬁgure 5 and show that, apart
from class 1, there were no conﬁrmed cases of mosaicism
in the analysis of blood ( ).np 24
In all apparently nonmosaic, nondeletion de novo cases
( ), we attempted to determine the parental originnp 20
of the mutation by establishing the phase of the mutant
allele with respect to a neighboring polymorphic site.
Most useful for this purpose was a highly polymorphic
(CA)n microsatellite located within intron 1 (c.129–485)
that has a heterozygosity of ∼90%. Patients with muta-
tions in the downstream exon 2 could be analyzed di-
rectly by allele-speciﬁc PCR ampliﬁcation, whereas, for
patients with mutations in exon 3, a two-stage process
of long-range PCR followed by cloning was required.
Four other less polymorphic SNPs were used in analysis
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of individual families. Representative examples of these
analyses are shown in ﬁgure 6. We established the pa-
rental origin of 14 of the 20 cases with de novo intra-
genic mutations: 13 originated from the father and 1
from the mother (table 1). With inclusion of the 3 de
novo deletions, there were 15 mutations of paternal or-
igin and 2 of maternal origin, which indicates a signif-
icant paternal excess (95% CI for proportion of paternal
mutations 0.64–0.99). For the 15 paternally originating
mutations, the mean (SE) of the paternal age at the
time of the child’s birth was years. This32.1 1.25
does not indicate a strong paternal age effect, a conclu-
sion that is supported by matching the nine subjects born
in England and Wales with the mean paternal age for
the year of birth: the mean of the paternal age excess
was years. Inclusion of the ﬁve uninforma-0.95 1.61
tive cases gave similar ﬁndings.
Discussion
The paradoxically greater phenotypic severity of CFNS
in females than in males and the apparent paucity of
carrier males has puzzled clinical geneticists for decades.
The identiﬁcation of causative mutations in EFNB1
makes it possible to explore the molecular bases of these
phenomena. In the present study, we extended our pre-
vious analysis of 20 EFNB1 mutations10 to include a
further 39 independent mutations, 27 of which are newly
described intragenic changes (table 1). The mutations
are diverse, which suggests partial or complete loss of
function in ephrin-B1. No genotype-phenotype correla-
tion is apparent, in agreement with previous studies.10,21
Most of the newly identiﬁed missense mutations occur
at completely or partly buried residues and are predicted
to disrupt protein folding,22 but three substitutions (at
N41, K113, and G123) locate at sites of interaction
between ephrin-B2 and EphB2.17 The mutation 993_
994insCT predicts a frameshift in the protein 15 aa from
the C terminus. This segment includes a PDZ-binding
domain, in the last 4 aa, that is required for binding of
intracellular targets,23 which suggests that disruption of
the reverse signaling activity of ephrin-B1 contributes to
the CFNS phenotype.21 This is consistent with the obser-
vation that removal of the terminal amino acid in murine
ephrin-B1 affects embryonic development.13
In addition to the intragenic mutations, we identiﬁed
three heterozygous deletions in individuals with typical
CFNS. Using a combination of microsatellite analysis
and breakpoint isolation, we showed that two deletions
do not involve any other gene but that the third disrupts
at least the centromeric gene STARD8. These patients
showed no consistent phenotypic differences compared
with those harboring intragenic mutations.
In an effort to understand the underrepresentation of
carrier males, we aimed to deﬁne the parental origin of
new germline mutations. A signiﬁcant advantage of the
present study, compared with those of X-linked recessive
disorders, was that the relative proportions of germline
mutations arising on the paternal and maternal X could
be estimated directly, which avoided the need to correct
for ascertainment bias.24 However, we encountered an-
other potential confounder: the occurrence of mosai-
cism, which indicated postzygotic mutation. Mutability
of the X chromosomes of maternal and paternal origin
in the early embryo might be similar, because imprinting
is erased at this stage25; thus, contamination with mosaic
cases would cause misinterpretation of parental origin
data for true germline mutations. Therefore, we ﬁrst
sought evidence of mosaicism, using Wave-DHPLC, re-
striction digests, and Pyrosequencing. Of note, at least
one case would not have been detected had we used
DNA sequencing as our only mutation detectionmethod
(ﬁg. 4C; see also Jones et al.26).
Once a mutation had been identiﬁed, we found that
use of restriction digests was an effective way to screen
for mosaicism. The digests were designed so that the
mutant allele abolished a restriction site; because of in-
complete extensions in the PCR at higher cycle numbers,
the ﬁnal product contains a signiﬁcant proportion of
heteroduplex molecules that are resistant to digestion.27
In high-level mosaics, the relative intensity of the non-
digested and digested fragments is reversed (ﬁg. 4B),
whereas low-level mosaics can be detected because a
majority of mutant molecules is present in heterodu-
plexes, nearly doubling the amount of PCR product re-
sistant to digestion (ﬁg. 4C). We could readily identify,
by Pyrosequencing estimates, mutations that were pre-
sent at the !5% level (ﬁg. 5).
To supplement this qualitative approach with a quan-
titative one, we used Pyrosequencing to show that pre-
sumptive high-level mosaic cases indeed deviated from
50:50 in the ratio of mutant:normal alleles (ﬁg. 4D).
To conﬁrmmosaicism, we assayed both strands indepen-
dently, compared the presumptive mosaic with a known
germline mutation, or sampled additional tissues (buccal
brushings and hair roots) (ﬁgs. 4 and 5). Artifactual ex-
planations, such as inadvertent contamination of the
sample with normal genomic DNA or PCR product, or
unequal allelic ampliﬁcation because of a polymorphism
underlying the PCR primer sequences were avoided by
repeat assays, DNA sequencing of primer binding regions,
and replication of results with use of different combi-
nations of primers.
Using these approaches, we conﬁrmed occult parental
mosaicism in 3 of 24 fully informative families and con-
ﬁrmed mosaicism of the ﬁrst affected female in 3 of 50
remaining eligible cases. An unbiased estimate of the
prevalence of mosaicism in new cases of EFNB1 mu-
tation is therefore 18.5%. These mosaic cases encom-
passed a wide variety of clinical presentations. In fe-
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Figure 5 Quantiﬁcation of proportion of mutated EFNB1 alleles in different patients and tissues. Samples from blood, buccal brushings,
and hair roots are indicated with blackened, gray, and unblackened symbols, respectively, and are plotted as the mean and range of measurements
from triplicate PCR products. For related individuals, mothers, fathers, and daughters are shown as squares, diamonds, and circles, respectively.
All other data are from unrelated, ﬁrst affected cases and are indicated as triangles. For clarity, the results are divided into four classes. From
left to right, these are (1) subjects in whom mosaicism was suspected and subsequently conﬁrmed (proportion of mutated EFNB1 allele !0.5),
(2) mother-daughter pairs with the same mutation, (3) unrelated subjects with the recurrent mutations 196CrT and 451GrA, and (4) 11
subjects for whom the parental origin was established (the other 3 cases are plotted in previous classes). Family numbers for the individual
points are shown in ﬁg. 1B.
Figure 4 Subjects with CFNS who are mosaic for EFNB1 mutations. A, Pedigrees of six conﬁrmed mosaics (squares represent males;
circles represent females; blackened symbols represent clinically affected individuals; a dot within the symbol represents a mosaic carrier with
mild clinical symptoms; na indicates that no DNA was available for analysis). For the mosaic individual in each pedigree, the percentage of
EFNB1 mutation in each tissue sampled is indicated. B, High-level gonosomal mosaicism in the unaffected mother of subject 3217. Photographs
show facial appearance of subject 3217 with clinical CFNS (below left), her mildly affected brother (below right), and her clinically unaffected
parents (top). Right, Diagnostic restriction digest of exon 2 PCR product. The 161CrT mutation abolishes a BslI site, which indicates that
subject 3217 is heterozygous and her brother is hemizygous for the mutation. In the mother, the ratio of mutant:normal alleles appears identical
to that of subject 3217 in DNA samples from blood but is reduced in the hair root and buccal samples. C, Low-level somatic mosaicism in
the blood of subject 3494 with CFNS. Left, Wave-DHPLC analysis of exon 3 PCR fragments from ﬁve different individuals. Superimposition
of the waveforms reveals abnormal migration of the fragment from subject 3494. Center, DNA sequencing of this fragment appeared normal
(upper trace, arrowhead indicates position of mutation). On sequencing individual clones of this fragment, 1 of 16 contained the mutation 407-
1GrA (lower trace). Right, Diagnostic restriction digest of exon 3 PCR product. The mutation abolishes a PstI site: only a small amount of
PstI-resistant product is present in the sample from subject 3494, compared with subject 347, who is constitutionally heterozygous for the same
mutation.10 Quantiﬁcation by Pyrosequencing showed that the mutation level was 13% (panel A). D, High-level somatic mosaicism in the blood
of subject 3412. Left, DNA sequencing of exon 2 PCR product showing apparent underrepresentation of the mutant 191GrA allele in the
patient (lower trace). Right, Quantiﬁcation by Pyrosequencing. The dispensation program for the forward Pyrosequencing primer is shown at
the top right. The ratio of the 191A:191G alleles was estimated by comparing peak heights at dispensations C6:C2 (which quantify ﬁve consecutive
C residues) and G7:G5. In the pyrograms (bottom right), peaks diagnostic of the 191A (mutant) and 191G (normal) alleles are indicated with
gray and black arrows, respectively. In the control sample, mutant peak heights are at background levels and fulﬁll quality-control criteria. In
the patient sample, note consistently lower heights for 191A peaks matched with 191G peaks. Quantiﬁcation of pyrograms from triplicate PCR
products, combined with data for the reverse Pyrosequencing primer, indicates that the 191GrA mutation was present at a 27% level in the
blood (panel A).
males, the most extreme contrasts are provided by the
mother in family 3217, who had minimal clinical man-
ifestations but appeared to have a constitutional (∼50%)
level of mutation in blood, although she had lower mu-
tation levels in hair root and buccal brushings (ﬁg. 4B),
and subject 3494, who despite having classic CFNS, had
a level of mutation in blood of only 13% (ﬁg. 4C). The
poor correlation between the measured level of mosai-
cism and clinical features presumably reﬂects variation
in mutation levels—and possibly X inactivation—in tis-
sues that we were unable to sample.
Several other genetic disorders have been described in
which somatic mosaicism for diverse intragenicmutations
accounts for 110% of new cases; for example, retino-
blastoma,28 tuberous sclerosis complex,29 hemophilia B,24
X-linked lissencephaly/double cortex syndrome,30 hemo-
philia A,31 and neuroﬁbromatosis 2.32 However, low lev-
els of somatic mosaicism for EFNB1 mutations may
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Figure 6 Analysis of the parental origin of EFNB1 mutations. Representative results from two patients are shown, each below a diagram
of the PCR strategy and product numbers (see tables 2 and 3 online only]). A, Patient 3575 (363CrA in exon 2) informative for CA c.129–
485. Left, Allele-speciﬁc PCR by use of mutation-speciﬁc primer (product 18), which conﬁrms presence of the mutation in the patient’s blood
but not in either parent. Right, (CA)n genotyping of the family (product 5) by blot hybridization. The mutation-speciﬁc PCR product contains
the paternal (CA)n allele, which indicates that the mutation arose from the father. B, Patient 3533 (123CrG in exon 1) informative for the
SNP 128235c/g. The g allele of the SNP creates a PstI restriction site. Left, PstI genotyping (product 2) showing that patient 3533 is heterozygous
for the SNP. Center, Allele-speciﬁc PCR by use of mutation-speciﬁc primer (product 14), which conﬁrms the presence of the mutation in blood
from the patient but not in either parent. Right, PstI genotyping of the allele-speciﬁc PCR product from patient 3533 showing that it contains
the g allele of the SNP, which indicates that the mutation arose from the mother.
be particularly likely to manifest, because the proposed
mechanism of the greater phenotypic severity in females
involves functional mosaicism (i.e., X inactivation). We
speculated that rare male cases with apparent pheno-
copies of CFNS might also be mosaics for an EFNB1
mutation, but we did not identify a mutation in two
such males, including a patient reported elsewhere.4 We
did ﬁnd mosaicism in one male, the father of a classically
affected female (family 3605); however, the mutation
was present at very low proportions in both his blood
(3%) and his hair roots (2%). This man had previously
fathered an unaffected girl, which indicates that he is
also mosaic in his testes; he manifested mild features of
the male-carrier state rather than a more severe CFNS-
like phenotype.
After this analysis, we were left with 20 families in
which both parents were negative for the apparent germ-
line intragenic mutation that was present in the child.
Of the 14 trios with a suitable polymorphism near the
mutation, 13 mutations originated from the father. After
incorporating data from the three deletions (two pater-
nal and one maternal in origin) and correcting for the
relative proportions of intragenicmutations anddeletions,
we estimated that ∼92% of de novo germline EFNB1
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mutations have a paternal origin. This pattern of pre-
dominant but not exclusive paternal mutations without
marked elevation in paternal age has been observed in
mutations of several other genes associated with loss
of function; for example, NF1,33 RB1,34 and MECP2.35
This suggests that age-independent factors, such as DNA
methylation, might be at least as important as replication
error in contributing to the male excess of mutations in
these genes.36 The situation for EFNB1 is clearly distinct
from craniosynostosis-associated mutations in FGFR2,
in which an exclusive paternal origin of mutations and
signiﬁcant paternal-age effect20 have been attributed to
positive selection of gain-of-function mutations in sper-
matogonial cells.37,38
The identiﬁcation of EFNB1 mutations enables us to
analyze why males are apparently underrepresented in
CFNS pedigrees. Our series includes eight hemizygous
males (table 1): six had typical mild features with hy-
pertelorism,4 and the remaining two had major mani-
festations that required surgical procedures shortly after
birth.39 We have not yet encountered a case in which a
father was thought to be unaffected, as assessed by a
dysmorphologist, but turned out to be hemizygous for
the mutation. This indicates that nonpenetrance is not
the major explanation for the paucity of carrier males.
Instead, we propose that three other factors contribute:
(1) the predominant paternal origin of de novo germline
EFNB1 mutations, since these can affect only females
in the ﬁrst generation; (2) the lower genetic ﬁtness of
heterozygous females compared with hemizygous males,
since carrier males for X-linked disorders can inherit a
mutation from their mother only; and (3) the occurrence
of postzygotic mutations, which are expected to occur
twice as frequently in female embryos and may also be
more likely to manifest clinically because of X inacti-
vation. For illustration, if we adopt a simple model of
mutation-selection equilibrium in which we ignore mo-
saicism, use a ratio of male:female germline EFNB1mu-
tations of 9:1, and assume that reproductive ﬁtness for
EFNB1-mutant hemizygous males and heterozygous fe-
males is 1.0 and 0.4, respectively, we calculate that 80%
of individuals harboring EFNB1 mutations would be
female, which accords with clinical observations (see the
introduction above).
Apart from theoretical interest, our ﬁndings are im-
portant for genetic counseling of patients with CFNS.
The speciﬁc information given to those who seek coun-
seling will depend on how conﬁdently mosaicism has
been excluded in the unaffected parental and ﬁrst af-
fected generations; in particular, the possibility of occult
germinal mosaicism in one of the parents of a child with
a germline mutation should be considered. Germinal
mosaicism can be conﬁdently excluded only if it is shown
that both (1) the mutation has arisen from the father
and (2) it is not present at signiﬁcant levels in the sperm.
It would be instructive to quantify the EFNB1 mutation
levels in the father’s sperm in cases of known paternal
origin. On the other hand, when it can be convincingly
demonstrated—as it was in several cases in the present
study—that the mutation is present at !50% levels in
at least one tissue, then it is likely to have arisen postzy-
gotically. In that situation, the recurrence risk for the
parents of this affected individual is likely to be low and
risk for the offspring of the affected individual might be
!50%, but female offspring inheriting the mutation
would do so in a nonmosaic state and might be more
severely affected. However, careful exclusion of artifac-
tual explanations of the apparent mosaicism would be
essential before counseling along those lines.
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